Triiodothyronine hormone supplementation therapy in septic shock patients with euthyroid sick syndrome: two pilot, placebo-controlled, randomized trials
Authors' conclusion
T3 supplementation was associated with a low 28-day mortality rate in patients with low T3T4 but with increased mortality in patients with low T3 ESS.
Study context
- Population
- Septic shock patients with euthyroid sick syndrome (ESS), divided by thyroid hormone values into low T3 and low T3T448 low T3, 47 low T3T4
- Participants
- 95 patients
- Comparison
- Triiodothyronine (T3) supplementation for 4 days vs placebo, in low T3 and low T3T4 subgroups
- T3 (low T3)n = 24
- Placebo (low T3)n = 24reference
- T3 (low T3T4)n = 24
- Placebo (low T3T4)n = 23reference
- Primary endpoint
- Survival
- Follow-up
- 28 days
Methodological detailstwo pilot trials, placebo-controlled
- Two pilot trials
- Placebo-controlled
Primary result
As reported in the abstract
Mortality
T3 (low T3) vs Placebo (low T3): P = 0.004 · T3 (low T3T4) vs Placebo (low T3T4): P = 0.039
Secondary outcomes
MAP (low T3T4) · day 1, day 3 and day 7
- Oral T3 increased MAP vs placebo
- p = 0.015, =0.005 and =0.042 respectively
MAP (low T3)
- No significant effect of T3
Original publication
Triiodothyronine hormone supplementation therapy in septic shock patients with euthyroid sick syndrome: two pilot, placebo-controlled, randomized trials. Anaesth Crit Care Pain Med. Published 5 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →